MARCHICA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 3.089
AS - Asia 2.456
EU - Europa 1.803
SA - Sud America 326
AF - Africa 171
Continente sconosciuto - Info sul continente non disponibili 131
OC - Oceania 2
Totale 7.978
Nazione #
US - Stati Uniti d'America 2.984
SG - Singapore 855
CN - Cina 601
VN - Vietnam 436
IT - Italia 394
SE - Svezia 303
IE - Irlanda 290
BR - Brasile 237
DE - Germania 182
HK - Hong Kong 178
FR - Francia 137
ZA - Sudafrica 107
BD - Bangladesh 99
FI - Finlandia 83
NL - Olanda 83
TR - Turchia 83
CA - Canada 69
GB - Regno Unito 67
AT - Austria 62
IN - India 42
RU - Federazione Russa 42
AR - Argentina 31
CZ - Repubblica Ceca 22
JP - Giappone 22
RO - Romania 22
BE - Belgio 20
IQ - Iraq 20
CI - Costa d'Avorio 18
ES - Italia 18
MX - Messico 18
PL - Polonia 18
TH - Thailandia 16
UA - Ucraina 14
PH - Filippine 13
PK - Pakistan 13
ID - Indonesia 12
VE - Venezuela 12
LT - Lituania 11
CL - Cile 10
EC - Ecuador 10
PY - Paraguay 10
CO - Colombia 9
KR - Corea 9
KE - Kenya 8
MA - Marocco 8
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
ET - Etiopia 6
EU - Europa 6
UZ - Uzbekistan 6
CR - Costa Rica 5
EG - Egitto 5
IL - Israele 5
TW - Taiwan 5
KH - Cambogia 4
SC - Seychelles 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
IR - Iran 3
JO - Giordania 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
OM - Oman 3
PE - Perù 3
QA - Qatar 3
RS - Serbia 3
TN - Tunisia 3
DK - Danimarca 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
MU - Mauritius 2
MZ - Mozambico 2
NP - Nepal 2
PT - Portogallo 2
SM - San Marino 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GD - Grenada 1
KI - Kiribati 1
Totale 7.843
Città #
Singapore 459
Ashburn 427
Chandler 333
San Jose 296
Dublin 286
Santa Clara 199
Hong Kong 171
Dallas 165
Parma 143
Ho Chi Minh City 136
Beijing 120
Johannesburg 102
New York 101
Hanoi 99
Ann Arbor 93
Los Angeles 93
Shanghai 92
Boardman 89
Council Bluffs 89
Dearborn 67
Munich 62
Vienna 57
Izmir 54
Lauterbourg 52
Nanjing 51
Princeton 45
Marseille 38
Buffalo 34
São Paulo 31
Helsinki 28
Wilmington 27
Columbus 25
Toronto 25
Milan 24
The Dalles 24
Bremen 23
Moscow 23
Shenyang 23
Turku 22
Orem 21
Tokyo 20
Da Nang 19
Abidjan 18
Brno 18
Brussels 18
Houston 16
Warsaw 16
Poplar 15
Rome 15
San Mateo 15
Frankfurt am Main 14
Hebei 14
Jinan 14
Kunming 14
Düsseldorf 13
Hefei 13
London 13
Montreal 13
Nanchang 13
Atlanta 12
Haiphong 12
Kocaeli 12
Modena 12
Amsterdam 11
Nuremberg 11
Stockholm 11
Ankara 10
Biên Hòa 10
Chennai 10
Denver 10
Focsani 10
Guangzhou 10
Jakarta 10
Redmond 10
Bologna 9
Brooklyn 9
Bangkok 8
Changsha 8
Chicago 8
Dhaka 8
Fairfield 8
Jiaxing 8
Ottawa 8
Phoenix 8
San Francisco 8
Woodbridge 8
Hải Dương 7
Manchester 7
Norwalk 7
Pune 7
Tianjin 7
Washington 7
Zhengzhou 7
Addis Ababa 6
Asunción 6
Boston 6
Can Tho 6
Charlotte 6
Hangzhou 6
Jacksonville 6
Totale 4.890
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 221
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 217
A simplified sars-cov-2 pseudovirus neutralization assay 213
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 212
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 198
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 196
Novel targets for the treatment of relapsing multiple myeloma 194
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 193
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 190
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 187
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 187
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 185
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 185
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 183
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 180
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 176
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 175
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 174
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 162
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 162
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 161
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 159
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 157
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 155
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 154
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 153
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 153
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 149
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 148
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 148
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 147
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 145
The impact of CD56 expression in smoldering myeloma patients on early progression 142
Oncolytic virotherapy and microenvironment in multiple myeloma 142
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 139
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 135
Possible targets to treat myeloma-related osteoclastogenesis 134
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 134
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 130
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 127
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 119
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 118
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 118
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 111
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 109
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 104
Role of Galectins in Multiple Myeloma. 102
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 100
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 99
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 96
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 92
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 90
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes 15
Use of bovine viruses as alternative tools in multiple myeloma oncolytic virotherapy 3
Totale 7.978
Categoria #
all - tutte 28.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.633


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022290 0 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/20251.531 27 60 84 140 162 142 106 87 194 119 144 266
2025/20263.257 318 244 362 301 469 201 341 111 400 276 133 101
2026/2027171 50 121 0 0 0 0 0 0 0 0 0 0
Totale 7.978